Overview

A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

Status:
Not yet recruiting

Trial end date:
2023-04-19

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to learn about the safety, tolerability, Pharmacokinetics (PK), and preliminary efficacy of ARV-471 as monotherapy in Japanese participants with ER+/HER2- locally advanced or metastatic breast cancer (mBC).

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Collaborator:

Arvinas Androgen Receptor, Inc.